# US 2003/0225080 A1 · Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225080 A1
- Document ID: US20030225080A1
- Status: Published application
- Kind: A1
- Application number: 10/463,814
- Filed: 2003-06-18
- Published: 2003-12-04
- Earliest claimed: 1997-04-22
- Assignees: Euro-Celtiques S.A.
- Inventors: Yan Wang; Sui Xiong Cai; Nancy C. Lan; John FW Keana; Victor I Ilyin; Eckard Weber
- Web page: https://patentgrep.com/patent/US20030225080A1

## CPC

- C07D 213/643: 2-Phenoxypyridines; Derivatives thereof
- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61K 31/175: having the group [IMAGE cpc-sch-A61K-0950.gif] , >N—C(O)—N=N— or[IMAGE cpc-sch-A61K-0951.gif] , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61P 9/06: Antiarrhythmics
- A61P 23/02: Local anaesthetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 281/12: the carbon atom being part of a ring other than a six-membered aromatic ring
- C07C 281/14: the carbon atom being further bound to a carbon atom of a six-membered aromatic ring
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- C07D 213/68: attached in position 4
- C07D 215/12: with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D 307/91: Dibenzofurans; Hydrogenated dibenzofurans
- C07D 309/12: only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
- C07D 317/50: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D 317/58: Radicals substituted by nitrogen atoms (nitro radicals C07D317/52)
- C07D 317/62: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D 317/64: Oxygen atoms
- C07D 319/18: Ethylenedioxybenzenes, not substituted on the hetero ring
- C07C 2601/14: The ring being saturated
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: 1 or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R1, R21, R22 and R23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; or R22 and R23, together with the N, form a heterocycle; A1 and A2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR24, CR25R26, C(O), NR24C(O), C(O)NR24, SO, SO2 or a covalent bond; where R24, R25 and R26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl. The invention also is directed to the use of carbocycle and heterocycle substituted semicarbazones and thiosemicarbazones for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), for the treatment and prevention of otoneurotoxicity and eye diseases involving glutamate toxicity and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy and urinary incontinence.

## Claims

### Claim 1

A method of treating a disorder responsive to the blockade of sodium channels in a mammal suffering therefrom, comprising administering to a mammal in need of such treatment an effective amount of a compound having the Formula I:
20
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Y is oxygen or sulfur;
R1 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl;
R21, R22 and R23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl, or R21, is defined as above, and R22 and R23 together with the nitrogen atom to which they are attached form a heterocycle selected from the group consisting of piperidine, piperazine and morpholine;
A1 and A2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted;
X is one or O, S, NR24, CR25R26, C(O), NR24C(O), C(O)NR24, SO, SO2 or a covalent bond; where
R24 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; and
R25 and R26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl;
provided when both Ar1 and Ar2 are phenyl and X is O or S, then said disorder is other than convulsions.

### Claim 2 (depends on 1)

The method according to claim 1, wherein A1 and A2 are both optionally substituted aryl moieties.

### Claim 3 (depends on 1)

The method according to claim 1, wherein
A1 and A2 are phenyl moieties, that are each independently optionally substituted by one or two substituents independently selected from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, cyano, C1-6 alkoxy and C6-10 aryloxy;
Y is O;
R1 is hydrogen, C1-6 alkyl, C3-8 cycloalkyl or C6-10 aryl;
R21, R22 and R23 are independently hydrogen or C1-6 alkyl; and
X is oxygen or sulfur.

### Claim 4 (depends on 1)

The method according to claim 1, wherein at least one of R21, R22 and R23 is C1-6 alkyl.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said compound is selected from the group consisting of:
4-phenoxybenzaldehyde semicarbazone;
4-(3,4-methylenedioxyphenoxy)benzaldehyde semicarbazone;
4-(4-fluorophenoxy)benzaldehyde semicarbazone;
4-(4-chlorophenoxy)benzaldehyde semicarbazone;
4-(4-bromophenoxy)benzaldehyde semicarbazone;
4-(4-methoxyphenoxy)benzaldehyde semicarbazone;
4-(4-trifluoromethylphenoxy)benzaldehyde semicarbazone;
4-(4-methylphenoxy)benzaldehyde semicarbazone;
4-(3,4-difluorophenoxy)benzaldehyde semicarbazone;
4-(4-chloro-2-fluorophenoxy)benzaldehyde semicarbazone;
4-(4-nitrophenoxy)benzaldehyde semicarbazone;
4-(3-methylphenoxy)benzaldehyde semicarbazone;
4-(4-t-butylphenoxy)benzaldehyde semicarbazone;
4-(4-propylphenoxy)benzaldehyde semicarbazone;
4-(4-s-butylphenoxy)benzaldehyde semicarbazone;
4-(4-bromophenoxy)acetophenone semicarbazone;
4-(4-fluorophenoxy)acetophenone semicarbazone;
4-(4-fluorophenoxy)-3-fluoroacetophenone semicarbazone;
4-(4-chlorophenoxy)acetophenone semicarbazone;
4-(4-bromophenoxy)propiophenone semicarbazone;
4-(4-fluorophenoxy)propiophenone semicarbazone;
4-(4-chlorophenoxy)propiophenone semicarbazone;
4-phenylmercaptobenzaldehyde semicarbazone;
4-(4-fluorophenylmercapto)benzaldehyde semicarbazone;
4-(4-chlorophenylmercapto)benzaldehyde semicarbazone;
4-cyclohexyloxybenzaldehyde semicarbazone;
4-cycloheptyloxybenzaldehyde semicarbazone;
4-(5-indanyloxy)benzaldehyde semicarbazone;
4-(6-quinolinyloxy)benzaldehyde semicarbazone;
4-(4-fluorophenoxy)-3-fluorobenzaldehyde semicarbazone;
4-(4-fluorophenoxy)cyclohexane-1-carboxaldehyde semicarbazone;
4-(tetrahydropyranyloxy)benzaldehyde semicarbazone;
4-(1-methyl-4-piperidinoxy)benzaldehyde semicarbazone;
4-(diphenylmethoxy)benzaldehyde semicarbazone;
4-(4-trifluoromethylphenoxy)benzaldehyde 2′-methylsemicarbazone;
4-(diphenylmethoxy)benzaldehyde 2′-methylsemicarbazone;
4-benzylbenzaldehyde 2′-methylsemicarbazone;
4-(5-indanyloxy)benzaldehyde 2′-methylsemicarbazone;
4-(3,4-methylenedioxyphenoxy)benzaldehyde 2′-methylsernicarbazone;
3-fluoro-4-(3,4-methylenedioxyphenoxy)benzaldehyde 2′-methylsemicarbazone;
4-(4-nitrophenoxy)benzaldehyde 2′-methylsemicarbazone;
4-(4-fluorophenoxy)-3-fluorobenzaldehyde 2′-methylsemicarbazone;
4-(4-fluorophenoxy)benzaldehyde 4′-methylsemicarbazone; and
4-(4-fluorophenoxy)benzaldehyde 2′-methylsemicarbazone.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said compound is selected from the group consisting of:
4-(2-pyridinoxy)benzaldehyde semicarbazone;
4-(3-pyridinoxy)benzaldehyde semicarbazone;
4-(4-pyridinoxy)benzaldehyde semicarbazone;
4-(4-chloro-2-pyridinoxy)benzaldehyde semicarbazone;
4-(2-pyrimidinoxy)benzaldehyde semicarbazone;
2-phenoxypyridine-5-carboxaldehyde semicarbazone;
2-(4-chlorophenoxy)pyridine-5-carboxaldehyde semicarbazone; and
2-(4-fluorophenoxy)pyridine-5-carboxaldehyde semicarbazone.

### Claim 7

A method for treating, preventing or ameliorating neuronal loss following global and focal ischemia; treating, preventing or ameliorating neurodegenerative conditions; treating, preventing or ameliorating otoneurotoxicity and eye diseases involving glutamate toxicity; treating, preventing or ameliorating pain; treating, preventing or ameliorating manic depression; providing local anesthesia; or treating arrhythmias and urinary incontinence, comprising administering to a mammal in need of such treatment an effective amount of a compound having the Formula I:
21
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Y is oxygen or sulfur;
R1 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl;
R21, R22 and R23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl, or R21, is defined as above, and R22 and R23 together with the nitrogen atom to which they are attached form a heterocycle selected from the group consisting of piperidine, piperazine and morpholine;
A1 and A2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted;
X is one or O, S, NR24, CR25R26, C(O), NR24C(O), C(O)NR24, SO, SO2 or a covalent bond; where
R24 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; and
R25 and R26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl.

### Claim 8 (depends on 7)

The method according to claim 7, wherein method is for treating, preventing or ameliorating pain and said pain is one of neuropathic pain, surgical pain or chronic pain.

### Claim 9 (depends on 7)

The method according to claim 7, wherein:
A1 and A2 are phenyl moieties, that are each independently optionally substituted by one or two substituents independently selected from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, cyanc, C1-6 alkoxy and C6-10 aryloxy;
Y is O;
R1 is hydrogen, C1-6 alkyl, C3-8 cycloalkyl or C6-10 aryl;
R21, R22 and R23 are independently hydrogen or C1-6 alkyl; and
X is oxygen or sulfur.

### Claim 10 (depends on 7)

The method of claim 7, wherein:
A1 is an optionally substituted aryl group selected from the group consisting of phenyl and naphthyl, and A2 is an optionally substituted heteroaryl or aryl group selected from the group consisting of pyridyl, pyrimidinyl, 1,3,5-triazinyl, furanyl, thiophenyl, naphthyl, quinolyl, 3,4-methylenedioxyphenyl, 3,4-ethylenedioxyphenyl, indanyl, tetrahydronaphthyl and quinoxalinyl.

### Claim 11 (depends on 7)

The method of claim 7, wherein
A1 is an optionally substituted aryl group selected from the group consisting of phenyl or naphthyl, and A2 is an optionally substituted carbocycle or heterocycle selected from the group consisting of cyclopentyl, cyclohexyl, cycloheptyl, piperidinyl, morpholinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, cyclohexenyl, adamantyl, exo-norbornyl and cyclopentenyl.

### Claim 12

A compound having the Formula I:
22
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Y is oxygen or sulfur;
R1 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl;
R21, R22 and R23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl, or R21, is defined as above, and R22 and R23 together with the nitrogen atom to which they are attached form a heterocycle selected from the group consisting of piperidine, piperazine and morpholine;
A1 and A2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted;
X is one or O, S, NR24, CR25R26, C(O), NR24C(O), C(O)NR24, SO, SO2 or a covalent bond; where
R24 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; and
R25 and R26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl;
provided that:
when X is O or S, and R21, R22 and R23 are hydrogen or alkyl, then A1 and A2 are not both phenyl, optionally substituted by one or two non-hydrogen substituents.

### Claim 13 (depends on 12)

A compound according to claim 12, wherein R21, R22 and R23 are independently hydrogen or alkyl.

### Claim 14 (depends on 12)

A compound according to claim 12, wherein at least one of R21, R22 and R23 is C1-6 alkyl.

### Claim 15 (depends on 12)

A compound according to claim 12, wherein R1 is hydrogen or alkyl.

### Claim 16 (depends on 12)

A compound according to claim 12, wherein X is O or S.

### Claim 17 (depends on 12)

A compound according to claim 12, wherein Y is oxygen.

### Claim 18 (depends on 12)

A compound according to claim 12, wherein
Y is oxygen;
R1 is hydrogen, alkyl, haloalkyl, or aryl;
R21, R22 and R23 are independently hydrogen or alkyl;
Ar1 is phenyl or naphthyl, optionally substituted with hydrogen, alkyl, haloalkyl, or halogen;
Ar2 is pyridinyl, pyrimidinyl, 1,3,5-triazinyl, 3,4-methylenedioxyphenyl, 3,4-ethylenedioxyphenyl, quinolinyl, quinoxalinyl or naphthyl, optionally substituted with hydrogen, alkyl, haloalkyl, or halogen; and
X is O or S.

### Claim 19 (depends on 12)

A compound according to claim 12, wherein
Y is oxygen;
R1 is hydrogen, alkyl, haloalkyl, or aryl;
R21, R22 and R23 are independently hydrogen or alkyl;
Ar1 is pyridinyl, pyrimidinyl, 1,3,5-triazinyl, quinolinyl, furanyl, thiophenyl or naphthyl, optionally substituted with hydrogen, alkyl, haloalkyl, or halogen,
Ar2 is phenyl, 3,4-methylenedioxyphenyl, 3,4-ethyelendioxyphenyl or naphthyl, optionally substituted with hydrogen, alkyl, haloalkyl, or halogen; and
X is O or S.

### Claim 20 (depends on 12)

A compound of claim 12, having Formula II or Formula III:
23
or a pharmaceutically acceptable salt or prodrug thereof, wherein
R1, R21, R22, R23, X, Y, A1 and A2 are as defined in claim 12, provided that A1 and A2 are other than optionally substituted phenyl; and
R3, R4, R5 and R6 independently are hydrogen, halo, haloalkyl, aryl, cycloalkyl, saturated or partially unsaturated heterocycle, heteroaryl, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl heteroarylalkyl, hetroarylalkenyl, heteroarylalkynyl, cycloalkylalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, nitro, amino, ureido, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido or alkylthiol; or
R3 and R4 or R5 and R6 form a bridge selected from the group consisting of
—OCH2O—, —OCF2O—, —(CH2)3—, —(CH2)4—OCH2CH2O—, —CH2N(R7)CH2—, —CH2CH2N(R7)CH2—, —CH2N(R7)CH2CH2— and —CH═CH—CH═CH—; where R7 is hydrogen, alkyl or cycloalkyl;
R8, R9, R10, R11 and R12 independently are hydrogen, halo, haloalkyl, aryl, cycloalkyl, saturated or partially unsaturated heterocycle, heteroaryl, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, cycloalkylalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, nitro, amino, ureido, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido or alkylthiol; or
one of R8 and R9, or R9 and R10, or R10 and R11, or R11 and R12 form a carbocycle or heterocycle selected from the group consisting of —OCH2O—, —OCF2O—, —(CH2)3—, —(CH2)4—, CH2CH2O—, —CH2N(R7)CH2, —CH2CH2N(R7)CH2—, —CH2N(R7)CH2CH2— and —CH═CH—CH═CH—; where R7 is hydrogen, alkyl or cycloalkyl.

### Claim 21 (depends on 12)

A compound of claim 12, having Formula IV or Formula V:
24
or a pharmaceutically acceptable salt or prodrug thereof, wherein
R1, R21, R22, R23, X, and Y are as defined in claim 12;
A, B, C, D and E are independently nitrogen or carbon, provided that no more than three of A, B, C, D and E are nitrogen, and there is no substituent, except for oxygen, present on A, B, C, D or E when said A, B, C, D or E represents nitrogen;
R3, R4, R5 and R6 independently are hydrogen, halo, haloalkyl, aryl, cycloalkyl, saturated or partially unsaturated heterocycle, heteroaryl, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, hetroarylalkenyl, heteroarylalkynyl, cycloalkylalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, nitro, amino, ureido, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido or alkylthiol; or
R3 and R4 or R5 and R6 form a bridge selected from the group consisting of
—OCH2O—, —OCF2O—, —(CH2)3—, —(CH2)4—, —OCH2CH2O—, —CH2N(R7)CH2—, —CH2CH2N(R7)CH2—, —CH2N(R7)CH2CH2— and
—CH═CH—CH═CH—; where R7 is hydrogen, alkyl or cycloalkyl; R8, R9, R10, R11 and R12 independently are hydrogen, halo, haloalkyl, aryl, cycloalkyl, saturated or partially unsaturated heterocycle, heteroaryl, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, cycloalkylalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, nitro, amino, ureido, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido or alkylthiol; or
one of R8 and RP, or R9 and R10, or R10 and R1 1, or R11 and R12 form a carbocycle or heterocycle selected from the group consisting of CH2O—, —OCF2O—, —(CH2)3—, —(CH2)4—, —OCH2CH2O—, —CH2N(R7)CH2—, —CH2CH2N(R7)CH2—, —CH2N(R7)CH2CH2— and —CH═CH—CH═CH—; where R7 is hydrogen, alkyl or cycloalkyl.

### Claim 22 (depends on 12)

A compound of claim 12, having the Formula VII or Formula VIII:
25
or a pharmaceutically acceptable salt or prodrug thereof, wherein
R1, R21, R22, R23, Y and X are as defined in claim 12;
B1 is an optionally substituted, saturated or partially unsaturated carbocycle or optionally substituted, saturated or partially unsaturated heterocycle; and
B2 is an optionally substituted, saturated or partially unsaturated carbocycle or optionally substituted, saturated or partially unsaturated heterocycle;
R3, R4, R5 and R6 independently are hydrogen, halo, haloalkyl, aryl, cycloalkyl, saturated or partially unsaturated heterocycle, heteroaryl, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, hetroarylalkenyl, heteroarylalkynyl, cycloalkylalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, nitro, amino, ureido, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido or alkylthiol; or
R3 and R4 or R5 and R6 form a bridge selected from the group consisting of
—OCH2O—, —OCF2O—, —(CH2)3—, —(CH2)4—, —OCH2CH2O—, —CH2N(R7)CH2—, —CH2CH2N(R7)CH2—, —CH2N(R7)CH2CH2— and
—CH═CH—CH═CH—; where R7 is hydrogen, alkyl or cycloalkyl;
R8, R9, R10, R11 and R12 independently are hydrogen, halo, haloalkyl, aryl, cycloalkyl, saturated or partially unsaturated heterocycle, heteroaryl, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, cycloalkylalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, nitro, amino, ureido, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido or alkylthiol; or
one of R8 and R9, or R9 and R10, or R10 and R11, or R11 and R12 form a carbocycle or heterocycle selected from the group consisting of —OCH2O—, —OCF2O—, —(CH2)3—, —(CH2)4—, —OCH2CH2O—, —CH2N(R7)CH2—, —CH2CH2N(R7)CH2—, —CH2N(R7)CH2CH2— and —CH═CH—CH═CH—; where R7 is hydrogen, alkyl or cycloalkyl.

### Claim 23 (depends on 22)

A compound according to claim 22, wherein B1 is cyclopentyl, cyclohexyl, cycloheptyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyfl or piperidinyl.

### Claim 24 (depends on 22)

A compound according to claim 22, wherein B2 is cyclopentyl, cyclohexyl, cycloheptyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl or piperidinyl.

### Claim 25 (depends on 12)

A compound according to claim 12, wherein said compound is
4-(3,4-methylenedioxyphenoxy)benzaldehyde semicarbazone;
4-cycloheptyloxybenzaldehyde semicarbazone; and
4-(5-indanyloxy)benzaldehyde semicarbazone 4-cyclohexyloxybenzaldehyde semicarbazone;
4-(tetrahydropyranyloxy)benzaldehyde semicarbazone;
4-(1-methyl-4-piperidinoxy)benzaldehyde semicarbazone;
4-(diphenylmethoxy)benzaldehyde semicarbazone;
4-(4-fluorophenoxy)benzaldehyde 2′-methylsemicarbazone;
4-(4-trifluoromethylphenoxy)benzaldehyde 2′-methylsemicarbazone;
4-(diphenylmethoxy)benzaldehyde 2′-methylsemicarbazone;
4-benzylbenzaldehyde 2′-methylsemicarbazone;
4-(5-indanyloxy)benzaldehyde 2′-methylsemicarbazone;
4-(3,4-methylenedioxyphenoxy)benzaldehyde 2′-methylsemicarbazone;
3-fluoro-4-(3,4-methylenedioxyphenoxy)benzaldehyde 2′-methylsemicarbazone;
4-(4-nitrophenoxy)benzaldehyde 2′-methylsemicarbazone;
4-(4-fluorophenoxy)-3-fluorobenzaldehyde 2′-methylsemicarbazone; and
4-(4-fluorophenoxy)benzaldehyde 4′-methylsemicarbazone.

### Claim 26 (depends on 12)

A compound according to claim 12, wherein said compound is selected from the group consisting of:
4-(2-pyridinoxy)benzaldehyde semicarbazone;
4-(3-pyridinoxy)benzaldehyde semicarbazone;
4-(4-pyridinoxy)benzaldehyde semicarbazone;
4-(4-chloro-2-pyridinoxy)benzaldehyde semicarbazone;
2-phenoxypyridine-5-carboxaldehyde semicarbazone;
2-(4-chlorophenoxy)pyridine-5-carboxaldehyde semicarbazone; and
2-(4-fluorophenoxy)pyridine-3-carboxaldehyde semicarbazone.

### Claim 27 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A pharmaceutical composition, comprising the compound of any one of claims 12-26, and a pharmaceutically acceptable carrier or diluent.
